14.3 Weight Reduction and Long-term Maintenance Study of WEGOVY Injection in Pediatric Patients Aged 12 Years and Older with Obesity Overview of Clinical Trial in Pediatric Patients WEGOVY injection was evaluated to reduce excess body weight in pediatric patients aged 12 years of age and older with obesity in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to 95th percentile standardized for age and sex (Study 10) (NCT#04102189)
Once patients reach effective obesity doses (2025 mg or higher daily), costs typically rise to $300 per month or more
Insulin resistance is the inadequate response of target tissues to the physiological effects of circulating insulin, such as decreased glucose uptake in skeletal muscles under insulin stimulation, inhibition of hepatic gluconeogenesis by insulin, and relief of the inhibitory effect of insulin on lipid breakdown in adipose tissue (Schenk et al., 2008)
When we looked into this issue last year, at least 13 states had introduced legislation dealing with coverage of GLP-1s by individual and group insurance plans or Medicaid
Check your unit-to-milligram conversions every time you prepare an injection, especially when starting a new vial or adjusting your dose
These medications should generally be avoided in patients with a history of pancreatitis
